Shopping Cart
- Remove All
- Your shopping cart is currently empty
Toripalimab is a recombinant, humanized immunoglobulin G4 (IgG4) monoclonal antibody that specifically targets and blocks the programmed cell death protein 1 (PD-1) immune checkpoint receptor, thereby acting as an immune checkpoint inhibitor used in clinical research for the investigation of advanced or metastatic malignancies, most notably nasopharyngeal carcinoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $81 | In Stock | |
5 mg | $207 | In Stock | |
10 mg | $330 | In Stock | |
25 mg | $660 | In Stock | |
50 mg | $1,060 | In Stock |
Description | Toripalimab is a recombinant, humanized immunoglobulin G4 (IgG4) monoclonal antibody that specifically targets and blocks the programmed cell death protein 1 (PD-1) immune checkpoint receptor, thereby acting as an immune checkpoint inhibitor used in clinical research for the investigation of advanced or metastatic malignancies, most notably nasopharyngeal carcinoma. |
In vivo | Methods: Toripalimab (0.3-10 mg/kg, intraperitoneal injection, twice a week, 6 times) was used to treat transgenic mice with human PD-1 knockout, and its therapeutic effect on tumors in mice was observed. Results: In the 1, 3, and 10 mg/kg treatment groups, tumor growth inhibition was observed in a dose-dependent manner, demonstrating significant anti-tumor efficacy. [1] |
Cas No. | 1924598-82-2 |
Color | Transparent |
Appearance | Liquid |
Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.